Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 19, 2021
Clinical care and therapeutic trials in PLSMary Kay Floeter, Deborah Warden, Dale Lange, et al.
Clinical Imaging|February 6, 2021
A specific biomarker for amyotrophic lateral sclerosis: Quantitative susceptibility mappingKathryn E Dean, Beiyi Shen, Gulce Askin, et al.
Plos One|November 13, 2012
Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS diseaseWei Zhao, Merina Varghese, Prashant Vempati, et al.
AJR. American Journal of Roentgenology|April 24, 2015
Quantitative susceptibility mapping of the motor cortex in amyotrophic lateral sclerosis and primary lateral sclerosisAndrew D Schweitzer, Tian Liu, Ajay Gupta, et al.
Clinical Imaging|October 5, 2018
Diffusion tensor imaging and quantitative susceptibility mapping as diagnostic tools for motor neuron disordersElizabeth K Weidman, Andrew D Schweitzer, Sumit N Niogi, et al.
Plos Medicine|October 31, 2024
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trialSteven Perrin, Shafeeq Ladha, Nicholas Maragakis, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
JAMA Neurology|February 18, 2020
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical TrialJames F Howard, Richard J Nowak, Gil I Wolfe, et al.
Pageof 1